NEW YORK, NY--(Marketwired - Feb 2, 2016) - Mizuho Securities USA (MSUSA) (
"We continue to build a premier U.S. equity research franchise that is a leader in actionable value-added investment idea generation and analysis," said John Koudounis, MSUSA President & CEO. "Salim comes to us with great depth of expertise in the biotech sector and will be a great addition to the firm."
Syed joins MSUSA from Evercore ISI, where he spent the previous six years as Director, Biotech/Pharma Equity Research. Prior to Evercore, he was an investment banker working on M & A and capital market transactions at Morgan Stanley, where he began his career. Syed earned a Bachelor of Business Administration degree at the University of Michigan.
"The expansion of research coverage with such an experienced and highly-regarded analyst as Salim further demonstrates our commitment to providing clients with a seasoned team of professionals and a first-rate research product," said Matt DeSalvo, Executive Managing Director and Head of MSUSA's Equity Division.
About Mizuho Securities USA
Mizuho Securities USA Inc. is a U.S. registered broker-dealer headquartered in New York City, with offices in Atlanta, Boston, Chicago, Hoboken (NJ), Houston, Los Angeles, San Francisco and London (UK). MSUSA provides a wide range of fixed income and equity securities products and investment banking services to institutional clients. MSUSA is one of only 22 firms designated as a Primary Dealer in U.S. Government and Agency securities. MSUSA also is a U.S. registered futures commission merchant ("FCM") and a member of most international futures exchanges. MSUSA's parent company, Mizuho Securities Co., Ltd., is a top-tier, full-service, Japanese securities firm and a core member of the Mizuho Financial Group. http://www.mizuhosecurities.com
Mizuho Financial Group, Inc. (